|
|
|
Basic InformationMore InformationLatest NewsHIV No Barrier to Getting Liver Transplant, Study FindsXofigo Approved for Prostate CancerTest Approved to Detect Faulty Lung Cancer GeneNew Drug May Help Immune System Fight CancerCancer Patients May Face Higher Bankruptcy OddsFDA Approves New Drug to Fight Advanced Prostate CancerMetformin Won't Aid Breast Cancer Survival in DiabeticsCreative Arts Therapies Up Mental Health for Cancer PatientsExperts Aim to Draw Attention to High Cancer Drug CostsCreative Arts May Help Cancer Patients CopeAgent Orange Tied to Lethal Prostate CancerScientists Discover More Genetic Clues to Testicular CancerSocializing May Ease Pain of Breast CancerGene Discovery May Offer Breakthrough for Rare LeukemiaRed Hair Pigment Might Raise Melanoma Risk: StudySkin Cancer Tx Mostly Surgical, Regardless of Life ExpectancyAATS: MnDCT Beats Chest X-Ray for Detecting Lung CancerProstate Cancer May Be Deadlier for the UninsuredSleep Woes Tied to Prostate Cancer Risk in StudyAUA: Incidence of Testicular Cancer Up Through 2009Study Links Timing of ER Visit to Prostate Cancer Survival OddsTesticular Cancer on Rise in U.S., Especially Among Hispanic MenUrologists' Group Issues Updated Guidelines on PSA TestAt-Home Drug Errors Common for Kids With Cancer, Research ShowsScientists Pinpoint Most Major Genes Behind Deadly Blood CancerImplants May Delay Breast Cancer Detection, Raise Death RiskComprehensive Analysis Supports SERMs for Cutting Breast CancerNovel System Proposed for Accountable Cancer CareWomen Smokers More Likely to Get Colon Cancer Than Men: StudyFor Some Seniors With Skin Cancer, Surgery Not Always Best ChoiceComprehensive Discussion With Docs Ups Cancer ScreeningHistory of Skin Cancer Linked to Secondary CancersIntegrated 2D, 3D Mammogram Improves Cancer DetectionSoaring Prices Keep Leukemia Drugs From Patients, Experts SayRace, Income Tied to Breast Cancer Treatment Delays, Reduced SurvivalObesity Tied to Risk of Prostate Cancer After Negative BiopsyNon-Melanoma Skin Cancers Tied to Risk for Other CancersObesity Linked to Prostate Cancer, Study FindsMammograms Can Measure How Breast Cancer Drug Is Working: StudyScientists Spot Cancer Metabolism ChangesMinorities Less Prone to Think They'll Get Cancer: StudyClinical Trials Helped One Woman's Fight Against CancerARRS: MASS Criteria, LDH Predict Survival in MelanomaScientists Create Breast Cancer Survival PredictorEndocrine Therapy Often Incomplete after Breast CancerEndometriosis Surgery Linked to Lower Ovarian Cancer RiskReview Suggests Breast Cancer Screens Should Be PersonalizedMenopause-Like Woes Hinder Breast Cancer Treatment: StudySmoking Raises Asbestos Workers' Cancer Risk, Study SaysGene May Boost Death Risk From Most Common Thyroid Cancer LinksBook Reviews |
| |
Common Liver Tests Can Predict Liver Cancer Risk
Updated: Oct 19th 2012
FRIDAY, Oct. 19 (HealthDay News) -- Common liver function tests, including measurement of alanine transaminase (ALT) and aspartate transaminase (AST) levels, can be used to reliably predict hepatocellular carcinoma (HCC) risk in the general population with average or unknown risk, according to research published in the Oct. 17 issue of the Journal of the National Cancer Institute.
Chi-Pang Wen, M.D., M.P.H., Dr.P.H., of the National Health Research Institutes in Zhunan, Taiwan, and colleagues conducted a prospective cohort study involving 130,533 subjects with known hepatitis C virus (HCV) test results and 298,051 subjects without HCV results to examine risk prediction models based on clinically available data.
Over an average of 8.5 years of follow-up, 1,668 incident HCCs occurred. The researchers found that age; sex; health history; HCV and hepatitis B virus (HBV) status; and serum levels of ALT, AST, and alfa-fetoprotein all significantly and independently predicted HCC risk. Discrimination was higher using a model with serum transaminases only, compared with HBV or HCV only (area under the curve [AUC] for transaminases, 0.912; AUC for HBV, 0.840; AUC for HCV, 0.841). Discrimination was improved by adding HBV and HCV data to the transaminase-only model (AUC, 0.933). The high discrimination accuracy and calibration of these models was validated internally.
"This simple tool for the general public more accurately assesses risk even among groups previously thought to be at low or average risk and may be helpful to educate and motivate individuals to pursue options beneficial in reducing their risk of liver cancer and all-cause mortality," the authors write.
Abstract
Full Text (subscription or payment may be required)
This article: Copyright © 2012 HealthDay. All rights reserved. |